| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | VIM; Vimentin |
| Entrez GeneID | 7431 |
| WB Predicted band size | Calculated MW: 54 kDa; Observed MW: 54 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic phosphopeptide corresponding to residues surrounding Ser56 of human Vimentin |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于Phospho-Vimentin (Ser56)抗体的参考文献示例(内容为虚构，仅供参考)：
1. **"Phosphorylation of Vimentin Ser56 during Mitosis Regulates Cytoskeletal Dynamics"**
*作者：Inagaki M, et al.*
摘要：研究揭示了Vimentin在Ser56位点的磷酸化由CDK1激酶介导，调控有丝分裂中中间丝的解聚与重组，影响细胞骨架稳定性。该抗体用于标记有丝分裂期细胞。
2. **"Phospho-Vimentin (Ser56) as a Marker of Epithelial-Mesenchymal Transition in Cancer"**
*作者：Mendez MG, et al.*
摘要：通过免疫组化分析，证明Ser56磷酸化Vimentin在肿瘤转移中高表达，与EMT进程相关，提示其作为癌症侵袭性生物标志物的潜力。
3. **"Aurora Kinase B Phosphorylates Vimentin at Ser56 to Promote Cell Motility"**
*作者：Tsujimura K, et al.*
摘要：发现Aurora B激酶通过磷酸化Vimentin Ser56调控细胞迁移，该抗体在侵袭性乳腺癌模型中验证了磷酸化修饰的功能。
4. **"Development of a Monoclonal Antibody Specific for Phospho-Vimentin (Ser56) in Neurodegenerative Models"**
*作者：Kusubata M, et al.*
摘要：报道了一种高特异性抗体的制备，应用于阿尔茨海默病模型，发现Ser56磷酸化与神经元损伤中的胶质细胞活化相关。
(注：以上文献为示例，实际引用需查询PubMed等数据库获取真实信息。)
Phospho-Vimentin (Ser56) antibodies are specialized tools used to detect vimentin protein phosphorylated at serine 56. a post-translational modification linked to dynamic cellular processes. Vimentin, a type III intermediate filament protein, is crucial for maintaining cytoskeletal integrity, cell migration, and organelle positioning. Its phosphorylation, particularly at Ser56. regulates filament disassembly and reorganization during mitosis, stress responses, or signaling events. This site is targeted by kinases such as CDK1. Aurora B, or Rho-associated kinase (ROCK), depending on cellular context.
These antibodies are widely applied in cancer research, as vimentin phosphorylation correlates with epithelial-mesenchymal transition (EMT), metastasis, and drug resistance. In neurodegenerative diseases, Ser56 phosphorylation may influence abnormal protein aggregation. The antibodies are validated for techniques like Western blotting, immunofluorescence, and immunohistochemistry, often using knockout/knockdown controls or phosphatase treatment to confirm specificity. Commercial versions are typically raised against synthetic phosphopeptides, with clonal variations affecting sensitivity across species or experimental models. Recent studies also explore its role in DNA damage response and ciliogenesis, expanding its relevance in cell cycle and developmental biology research. Proper validation remains critical due to potential cross-reactivity with other phospho-epitopes or isoforms.
×
